Sharon Worcester on Muck Rack

Sharon Worcester

Verified
Birmingham
As seen in: MDedge Hematology and Oncology, Medscape, WebMD, Medscape France, Medscape Noticias Médicas, Medscape PT, Clinical Neurology News, Internal Medicine News, MDEdge, MDedge | Cardiology News, MDedge Dermatology, MdEdge ObGyn and
Medical journalist. Writer. Believer in love and hope and science. Ally. Views my own. She/Her. Latest book: The Doctor As The Patient
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Sharon

Contact Sharon, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

OPTIMA Supports Therapy De-escalation in High-Risk Breast Cancer

|
By Sharon Worcester 
| Medscape
About two thirds of patients with high-risk ER-positive, HER2-negative early breast cancer had similar outcomes whether or not they received chemotherapy alongside endocrine therapy, suggesting many may be able to safely avoid chemotherapy, according to findings from the phase 3 OPTIMA trial.
Open in Who Shared Issue with article?

Durvalumab Plus BCG Earns FDA Nod for Bladder Cancer

|
By Sharon Worcester 
| Medscape
The FDA has approved durvalumab (Imfinzi, AstraZeneca) in combination with Bacillus Calmette-Guerin (BCG) for adults with BCG-naive, high-risk non-muscle-invasive bladder cancer (NIMBC). Approval was based on findings from the randomized, open-label POTOMAC study of 1018 patients with high-risk NIMBC who had undergone transurethral bladder tumor resection, according to the FDA approval notice.
Open in Who Shared Issue with article?

FDA Approves Novel Targeted Therapy for Rare Blood Cancer

|
By Sharon Worcester 
| Medscape
The FDA has approved pivekimab sunirine-pvzy (Decnupaz, AbbVie, Inc.), a first-in-class CD123-directed antibody and alkylating agent conjugate, for the treatment of adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN). The approval, which followed breakthrough designation, orphan drug designation, and priority review, was based on efficacy demonstrated in the open-label, single-arm CADENZA trial of patients with BPDCN — an ultra-rare and aggressive hematologic malignancy.
Open in Who Shared View Duplicates (2) Issue with article?
See all 1,232 articles

Actions

Share this page

Get in touch with Sharon

Contact Sharon, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified